Skip to main content
SpringerLink
Log in

Igf system components as prognostic markers in breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The insulin-like growth factor (IGF) family of ligands, receptors, and binding proteins can regulate breast cancer cell proliferation in vitro, and interruption of these pathways inhibits IGF-mediated cell proliferation. If the IGF family members are key regulators of breast cancer growth and progression in vivo, we would expect their expression to be an indicator of the prognosis of the disease. Thus, measurement of IGF expression may provide an indicator of the growth effect within a tumor, and provide new targets for treatment of the disease. In this review we will summarize the data generated thus far indicating that IGF family members are indicators of prognosis of breast cancer, and that measurement of the whole IGF family in concert may provide useful information for treatment strategies of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Baker J, Liu J-P, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82, 1993

    Google Scholar 

  2. Liu J-P, Baker J, Perkins AS, Robertson E, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin like growth factor I (IGF-1) and type 1 IGF receptor (igflr). Cell 75:59–72, 1993

    Google Scholar 

  3. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249–252, 1995

    Google Scholar 

  4. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415–421, 1995

    Google Scholar 

  5. Yee D: The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32:85–95, 1994

    Google Scholar 

  6. Lee AV, Weng C-N, Jackson JG, Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152:39–47, 1997

    Google Scholar 

  7. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494, 1995

    Google Scholar 

  8. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS: Peptide growth factors cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinol 137:1735–1744, 1996

    Google Scholar 

  9. Yee D, Paik S, Levovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509–517, 1989

    Google Scholar 

  10. Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A, Lippman M, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48:6691–6696, 1988

    Google Scholar 

  11. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31–38, 1992

    Google Scholar 

  12. Giani C, Cullen KJ, Campani D, Rasmussen A: IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 41:43–50, 1996

    Google Scholar 

  13. Cullen K, Yee D, Sly W, Perdue J, Hampton B, Lippman M, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48–53, 1990

    Google Scholar 

  14. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch T, Cullen KJ: Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55:2448–2454, 1995

    Google Scholar 

  15. Osborne CK, Coronado EB, Kitten LJ, Arteaga CR, Fuqua SAW, Ramasharma K, Marshall M, Li CH: Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701–1709, 1989

    Google Scholar 

  16. Lee AV, Darbre P, King RJB: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 99:211–220, 1994

    Google Scholar 

  17. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in human breast cancer. Br J Cancer 74:1242–1247, 1996

    Google Scholar 

  18. Toropainen EM, Lipponen PK, Syrjanen KJ: Expression of insulin-like growth factor II in human breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res 15:2669–2674, 1995

    Google Scholar 

  19. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29:492–497, 1993

    Google Scholar 

  20. Pollack MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91–100, 1992

    Google Scholar 

  21. Barni S, Lissoni P, Brivio F, Fumugalli, Merlini D, Cataldo M, Rovelli F, Tancini G: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 80:212–215, 1994

    Google Scholar 

  22. Bhatavedar JM, Patel DD, Karclia NH, Vora HH, Ghosh N, Shah NG, Balar DB, Trivedi SN: Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study. Breast Cancer Res Treat 30:293–297, 1994

    Google Scholar 

  23. Peyrat J-P, Bonneterre J, Beuscart R, Djiane J, Demaille A: Insulin-like growth factor I receptors in human breast cancer and their relationship to estradiol and progesterone receptors. Cancer Res 48:6429–6433, 1988

    Google Scholar 

  24. Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343–1347, 1988

    Google Scholar 

  25. Foekens JA, Portengen H, Jansen M, Klun G: Insulin-like growth factor-I receptors and insulin-like growth factor-I-like activity in human primary breast cancer. Cancer 63:2139–2147, 1989

    Google Scholar 

  26. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50:6931–6935, 1990

    Google Scholar 

  27. Papa V, Gliozzo B, Clark G, McGuire W, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine I, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736–3740, 1993

    Google Scholar 

  28. Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID: Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: Potential autocrine role of IGF-II. Mol Endocrinol 5:709–717, 1991

    Google Scholar 

  29. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85, 1992

    Google Scholar 

  30. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036–1039, 1990

    Google Scholar 

  31. Nishimito I, Murayama Y, Katada T, Ui M, Ogata E: Possible direct linkage of insulin-like growth factor II receptor with guanine nucleotide-binding proteins. J Biol Chem 264:14029–14038, 1989

    Google Scholar 

  32. Karner C, Nurnberg B, Uhde M, Braulke T: Mannose-6-phosphate/insulin-like growth factor II receptor fails to interact with G-proteins. Analysis of mutant cytoplasmic receptor domains. J Biol Chem 270:287–295, 1995

    Google Scholar 

  33. McGuire W Jr, Jackson JG, Figueroa JA, Shimasaki SA, Powell DR, Yee D: Regulation of insulin-like growth factor binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336–13411, 1992

    Google Scholar 

  34. Yee D, Sharma J, Hilsenbeck SG: Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 86:1785–1789, 1994

    Google Scholar 

  35. Shao Z-M, Sheikh MS, Ordonez JV, Feng P, Kute T, Chen J-C, Aisner S, LeRoith D, Roberts CT, Fontana J: IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma. Cancer Res 52:5100–5103, 1992

    Google Scholar 

  36. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK: Insulin-like growth factor binding protein secretion by breast cancer cell lines: correlation with estrogen receptor status. Endocrinol 127:2679–2686, 1990

    Google Scholar 

  37. Yee D, Favoni R, Lippman M, Powell D: Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18:3–10, 1991

    Google Scholar 

  38. Rocha R, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D: Insulin-like growth factor binding protein-3 (BP3) mRNA and protein expression are correlated in primary breast cancer tissue; higher levels are detected in tumors with poor prognostic features. J Natl Cancer Inst 88:601–606, 1996

    Google Scholar 

  39. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C-N, Lee AV, Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and discase-free survival. Clinical Cancer Research 3:103–109, 1997

    Google Scholar 

  40. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229–233, 1993

    Google Scholar 

  41. Diamandis EP, Yu H, Sutherland DJA: Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32:301–310, 1994

    Google Scholar 

  42. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger B, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646–649, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Adrian V. Lee, Susan G. Hilsenbeck & Douglas Yee

Authors
  1. Adrian V. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan G. Hilsenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, A.V., Hilsenbeck, S.G. & Yee, D. Igf system components as prognostic markers in breast cancer. Breast Cancer Res Treat 47, 295–302 (1998). https://doi.org/10.1023/A:1005915420341

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005915420341

Search

Navigation